ESMO® 2025 Highlights: Presenter Vignette – Paul Cottu

Dr. Paul Cottu

Paul Cottu

PD, PhD

Institut Curie

296O

Risk of Recurrence (ROR) After Neoadjuvant Ribociclib Plus ET in Clinically High-Risk ER+/HER2− BC: Preliminary Analysis of the SOLTI-RIBOLARIS Trial